Changbaig Hyun
Changbaig Hyun has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Jiyoung Park
Hyun Changbaig Animal Heart Institute, VIP Animal Medical Center, Republic of Korea
3 shared publicationsJiyoon Lee
Hyun Changbaig Animal Heart Institute, VIP Animal Medical Center, Republic of Korea
2 shared publicationsSang-Joon Lee
Hyun Changbaig Animal Heart Institute, VIP Animal Medical Center, Republic of Korea
2 shared publicationsJi-Heui Sohn
VIP Animal Medical Center (Chungdam), Seoul, Korea 06068
1 shared publicationJong-In Kim
VIP Animal Medical Center (Chungdam), Seoul, Korea 06068
1 shared publication- Ran Choi
Section of Small Animal Internal Medicine, College of Veterinary Medicine, Kangwon National University, 1 Kangwondaehak-gil, Chuncheon-si, Gangwon-do, 24341, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 11 September 2025
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 12, 1687939
Correction: Clinical evaluation of a novel fixed-dose combination tablet (Sentorpil® ForteGold) versus compounded powdered medications in dogs with myxomatous mitral valve disease: a randomized, double-blind study
The original version of this article has been updated. In the published article, there was a mistake in the Funding statement. The funding statement for the Key Development Project of the Department of Science and Technology was displayed as "2015CBd051". The correct statement is "Key Development Project of Department of Science and Technology (2015C03Bd051).'' Correction: Clinical Evaluation of a Novel Fixed-Dose Combination Tablet (ForteGold) Versus Compounded Powdered Medications in Dogs with Myxomatous Mitral Valve Disease: A Randomized, Double-Blind Study Article title The title of this article was erroneously given as: Clinical Evaluation of a Novel Fixed-Dose Combination Tablet (Sentorphil® ForteGold) Versus Compounded Powdered Medications in Dogs with Myxomatous Mitral Valve Disease: A Randomized, Double-Blind Study. The correct title of the article is Clinical Evaluation of a Novel Fixed-Dose Combination Tablet (Sentorpil® ForteGold) Versus Compounded Powdered Medications in Dogs with Myxomatous Mitral Valve Disease: A Randomized, Double-Blind Study. Abstract Adding/removing text In the abstract, [Sentorphil® ]. This has been corrected to read: Sentorpil® Text correction Adding/removing text Can you change "Sentorphil® " to " Sentorpil® " in the whole manuscript.
- 11 September 2025
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 12, 1687939
Open AccessCorrection: Clinical evaluation of a novel fixed-dose combination tablet (Sentorpil® ForteGold) versus compounded powdered medications in dogs with myxomatous mitral valve disease: a randomized, double-blind study
The original version of this article has been updated. In the published article, there was a mistake in the Funding statement. The funding statement for the Key Development Project of the Department of Science and Technology was displayed as "2015CBd051". The correct statement is "Key Development Project of Department of Science and Technology (2015C03Bd051).'' Correction: Clinical Evaluation of a Novel Fixed-Dose Combination Tablet (ForteGold) Versus Compounded Powdered Medications in Dogs with Myxomatous Mitral Valve Disease: A Randomized, Double-Blind Study Article title The title of this article was erroneously given as: Clinical Evaluation of a Novel Fixed-Dose Combination Tablet (Sentorphil® ForteGold) Versus Compounded Powdered Medications in Dogs with Myxomatous Mitral Valve Disease: A Randomized, Double-Blind Study. The correct title of the article is Clinical Evaluation of a Novel Fixed-Dose Combination Tablet (Sentorpil® ForteGold) Versus Compounded Powdered Medications in Dogs with Myxomatous Mitral Valve Disease: A Randomized, Double-Blind Study. Abstract Adding/removing text In the abstract, [Sentorphil® ]. This has been corrected to read: Sentorpil® Text correction Adding/removing text Can you change "Sentorphil® " to " Sentorpil® " in the whole manuscript.
- Open Access
- 12 August 2025
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 12
Clinical evaluation of a novel fixed-dose combination tablet (Sentorpil® ForteGold) versus compounded powdered medications in dogs with myxomatous mitral valve disease: a randomized, double-blind study
Introduction: Myxomatous mitral valve disease (MMVD) is a prevalent cardiac condition in older, small-breed dogs, often managed with multiple medications. Traditional administration involves compounded powdered mixtures, which may lead to dosing inaccuracies and reduced compliance.Methods: In a randomized, double-blind clinical trial, 60 client-owned dogs diagnosed with ACVIM stage C MMVD were assigned to receive either a novel fixed-dose combination tablet (Sentorpil® ForteGold) or a compounded powdered mixture of torsemide, pimobendan, enalapril, and spironolactone. Treatments were administered twice daily over 56 days. Clinical signs, blood chemistry, electrolyte levels, thoracic radiography, echocardiography, and biomarkers (NT-proBNP, SDMA, and cPL) were evaluated at baseline and on days 7, 14, 28, and 56.Results: Both groups exhibited significant improvements in clinical signs, including exercise intolerance, appetite, respiratory effort, and coughing, with the ForteGold group showing earlier and more sustained responses. Blood chemistry and electrolyte levels remained within normal ranges, indicating a favorable safety profile. Radiographic assessments revealed a gradual decrease in vertebral heart score and normalization of lung fields by Day 56 in both groups. Echocardiographic parameters (LA/Ao, LVIDd/Ao, MVE) improved significantly, with the ForteGold group demonstrating earlier enhancements. NT-proBNP levels decreased in both groups, with a more pronounced reduction in the ForteGold group. No significant changes were observed in SDMA and cPL levels, suggesting stable renal and pancreatic functions.Discussion: The fixed-dose combination tablet (Sentorpil® ForteGold) offers a clinically effective and safer alternative to compounded powdered medications for managing MMVD in dogs. Its formulation ensures accurate dosing, improved owner compliance, and enhanced clinical outcomes. Further studies with larger populations and extended follow-up periods are warranted to confirm these findings.
- 12 August 2025
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 12
Open AccessClinical evaluation of a novel fixed-dose combination tablet (Sentorpil® ForteGold) versus compounded powdered medications in dogs with myxomatous mitral valve disease: a randomized, double-blind study
Introduction: Myxomatous mitral valve disease (MMVD) is a prevalent cardiac condition in older, small-breed dogs, often managed with multiple medications. Traditional administration involves compounded powdered mixtures, which may lead to dosing inaccuracies and reduced compliance.Methods: In a randomized, double-blind clinical trial, 60 client-owned dogs diagnosed with ACVIM stage C MMVD were assigned to receive either a novel fixed-dose combination tablet (Sentorpil® ForteGold) or a compounded powdered mixture of torsemide, pimobendan, enalapril, and spironolactone. Treatments were administered twice daily over 56 days. Clinical signs, blood chemistry, electrolyte levels, thoracic radiography, echocardiography, and biomarkers (NT-proBNP, SDMA, and cPL) were evaluated at baseline and on days 7, 14, 28, and 56.Results: Both groups exhibited significant improvements in clinical signs, including exercise intolerance, appetite, respiratory effort, and coughing, with the ForteGold group showing earlier and more sustained responses. Blood chemistry and electrolyte levels remained within normal ranges, indicating a favorable safety profile. Radiographic assessments revealed a gradual decrease in vertebral heart score and normalization of lung fields by Day 56 in both groups. Echocardiographic parameters (LA/Ao, LVIDd/Ao, MVE) improved significantly, with the ForteGold group demonstrating earlier enhancements. NT-proBNP levels decreased in both groups, with a more pronounced reduction in the ForteGold group. No significant changes were observed in SDMA and cPL levels, suggesting stable renal and pancreatic functions.Discussion: The fixed-dose combination tablet (Sentorpil® ForteGold) offers a clinically effective and safer alternative to compounded powdered medications for managing MMVD in dogs. Its formulation ensures accurate dosing, improved owner compliance, and enhanced clinical outcomes. Further studies with larger populations and extended follow-up periods are warranted to confirm these findings.
- 29 February 2024
- Vol. 65 (3) , 221-226
Successful interventional occlusion of muscular ventricular septal defect in a dog.
Ventricular septal defect (VSD) is a rare congenital heart disease in dogs. Hemodynamically important interventricular defects must be closed to improve the prognosis. This case report describes successful interventional transcatheter closure of a muscular VSD in a young Maltese and poodle mixed-breed dog with a large muscular interventricular defect (~5 mm in diameter) with a high rate of left-to-right shunt flow. The VSD was closed with a customized Amplatzer-type VSD occluder via a percutaneous transvenous (jugular) approach. We concluded that interventional occlusion of a muscular VSD with an Amplatzer-type occluder is a viable treatment option for dogs. A regular follow-up study for this dog is ongoing and has not detected complications. Key clinical message: Interventional occlusion of a muscular VSD with an Amplatzer-type occluder is a viable treatment option for dogs.
- 29 February 2024
- Vol. 65 (3) , 221-226
Successful interventional occlusion of muscular ventricular septal defect in a dog.
Ventricular septal defect (VSD) is a rare congenital heart disease in dogs. Hemodynamically important interventricular defects must be closed to improve the prognosis. This case report describes successful interventional transcatheter closure of a muscular VSD in a young Maltese and poodle mixed-breed dog with a large muscular interventricular defect (~5 mm in diameter) with a high rate of left-to-right shunt flow. The VSD was closed with a customized Amplatzer-type VSD occluder via a percutaneous transvenous (jugular) approach. We concluded that interventional occlusion of a muscular VSD with an Amplatzer-type occluder is a viable treatment option for dogs. A regular follow-up study for this dog is ongoing and has not detected complications. Key clinical message: Interventional occlusion of a muscular VSD with an Amplatzer-type occluder is a viable treatment option for dogs.
- Open Access
- 25 August 2021
- Published by IntechOpen
Echocardiographic Features in Canine Myxomatous Mitral Valve Disease: An Animal Model for Human Mitral Valve Prolapse
Myxomatous mitral valve disease (MMVD) is the most common heart disease in dogs and has many similarities to human mitral valve prolapse (MVP). Transthoracic echocardiography is a non-invasive method for making a diagnosis and predicting the progression of heart failure (HF) in dogs and humans with mitral regurgitation (MR). It enables clinicians to detect the mitral valve (MV) lesions, to evaluate MR severity, and to assess its impact on cardiac remodeling, myocardial function, left ventricular (LV) filling pressures, as well as pulmonary arterial pressure. Furthermore, advanced ultrasound technologies such as tissue Doppler imaging (TDI), strain and strain rate imaging, and two-dimensional (2D) speckle tracking echocardiography (STE) provide a better assessment of global and regional myocardial function. Although the severity of MR and HF in dogs with MMVD is being evaluated as similar to human cardiology, the veterinary cardiologists are more focused on the severity of cardiac remodeling and cardiac dysfunction caused by MR, because surgical restoration of defected mitral apparatus is rarely done in dogs. The chapter will review conventional echocardiographic features of MMVD in dogs to provide a better understanding of the similarities and discrepancies between canine MMVD and human MVP to veterinary and human cardiologists and researchers.
- 25 August 2021
- Published by IntechOpen
Open AccessEchocardiographic Features in Canine Myxomatous Mitral Valve Disease: An Animal Model for Human Mitral Valve Prolapse
Myxomatous mitral valve disease (MMVD) is the most common heart disease in dogs and has many similarities to human mitral valve prolapse (MVP). Transthoracic echocardiography is a non-invasive method for making a diagnosis and predicting the progression of heart failure (HF) in dogs and humans with mitral regurgitation (MR). It enables clinicians to detect the mitral valve (MV) lesions, to evaluate MR severity, and to assess its impact on cardiac remodeling, myocardial function, left ventricular (LV) filling pressures, as well as pulmonary arterial pressure. Furthermore, advanced ultrasound technologies such as tissue Doppler imaging (TDI), strain and strain rate imaging, and two-dimensional (2D) speckle tracking echocardiography (STE) provide a better assessment of global and regional myocardial function. Although the severity of MR and HF in dogs with MMVD is being evaluated as similar to human cardiology, the veterinary cardiologists are more focused on the severity of cardiac remodeling and cardiac dysfunction caused by MR, because surgical restoration of defected mitral apparatus is rarely done in dogs. The chapter will review conventional echocardiographic features of MMVD in dogs to provide a better understanding of the similarities and discrepancies between canine MMVD and human MVP to veterinary and human cardiologists and researchers.
- 1 October 2020
- Vol. 84 (4) , 265-271
Evaluation of red blood cell profiles in dogs with heartworm disease
Recent studies have found that anemia and anisocytosis are precipitating factors for certain heart diseases in dogs. This study evaluated the prevalence and correlation of anemia and red blood cell distribution width (RDW) in dogs with heartworm disease (HWD). The study population consisted of 20 healthy control dogs and 86 dogs with HWD: 28 dogs with no clinical signs or pulmonary hypertension (Group 1), 42 dogs with mild clinical signs but no pulmonary hypertension (Group 2), and 16 dogs with severe clinical signs and pulmonary hypertension (Group 3). Along with echocardiographic interrogation of pulmonary hypertension, red blood cell (RBC) profiles were evaluated, including RDW. The total number of red blood cells (tRBCs), hematocrit (HCT), and hemoglobin (HGB) concentration was significantly lower in Group 3 dogs compared to control dogs (P < 0.05), while the RDW was significantly higher in Group 3 dogs than in control dogs (P < 0.05). The RDW was closely correlated to other RBC profiles and the presence of pulmonary hypertension (P < 0.05). The severity of tricuspid regurgitant gradient (TRG) was closely correlated with Hb and tRBC (P < 0.05), but not with the RDW and reticulocyte count. This study finding indicated that anemia and anisocytosis are common complications in dogs with severe clinical signs and pulmonary hypertension caused by heartworm disease (HWD). It would therefore be beneficial for clinicians to routinely check red blood cell (RBC) profiles, including RDW, in order to monitor the progression of heartworm disease in dogs.
- 1 October 2020
- Vol. 84 (4) , 265-271
Evaluation of red blood cell profiles in dogs with heartworm disease
Recent studies have found that anemia and anisocytosis are precipitating factors for certain heart diseases in dogs. This study evaluated the prevalence and correlation of anemia and red blood cell distribution width (RDW) in dogs with heartworm disease (HWD). The study population consisted of 20 healthy control dogs and 86 dogs with HWD: 28 dogs with no clinical signs or pulmonary hypertension (Group 1), 42 dogs with mild clinical signs but no pulmonary hypertension (Group 2), and 16 dogs with severe clinical signs and pulmonary hypertension (Group 3). Along with echocardiographic interrogation of pulmonary hypertension, red blood cell (RBC) profiles were evaluated, including RDW. The total number of red blood cells (tRBCs), hematocrit (HCT), and hemoglobin (HGB) concentration was significantly lower in Group 3 dogs compared to control dogs (P < 0.05), while the RDW was significantly higher in Group 3 dogs than in control dogs (P < 0.05). The RDW was closely correlated to other RBC profiles and the presence of pulmonary hypertension (P < 0.05). The severity of tricuspid regurgitant gradient (TRG) was closely correlated with Hb and tRBC (P < 0.05), but not with the RDW and reticulocyte count. This study finding indicated that anemia and anisocytosis are common complications in dogs with severe clinical signs and pulmonary hypertension caused by heartworm disease (HWD). It would therefore be beneficial for clinicians to routinely check red blood cell (RBC) profiles, including RDW, in order to monitor the progression of heartworm disease in dogs.